This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

WIRB-Copernicus Group Announces Release Of IRBNet National Research Network® 2012 Benchmark Report

"Institutions large and small struggle with the challenge of maintaining the financial viability of their research programs," said Stuart Horowitz, Ph.D., President of Institutions & Institutional Services at WIRB-Copernicus Group. "Although there are several means by which institutions can address this challenge, they must first independently and objectively assess their performance and position in the research market. The IRBNet National Research Network Benchmark Report is the only available source of data to help them to do that."

Download the IRBNet National Research Network 2012 Benchmark Report at: http://irbnetresources.org/news/benchmark2012.html

About IRBNet A WIRB-Copernicus Group Company

IRBNet offers the world's most widely used electronic solution for managing research compliance for institutions of any size, with more than 1,700 large, medium and small research institutions, boards and research sites registered on the National Research Network®. National Research Network® members benefit from secure online access to comprehensive research oversight tools anywhere, anytime, including real-time collaboration between investigators and institutions anywhere in the world. The National Research Network Enterprise Portal further enables institutions to navigate the complex federal ethics compliance requirements governing human, animal, and recombinant DNA research, while seamlessly managing Conflict of Interest, Sponsored Programs and other critical research oversight activities. With the release of the National Research Network 2012 Benchmark Report, IRBNet's unparalleled data-driven performance metrics make it easier than ever for universities and colleges, community hospitals, hospital networks, and federal and state agencies to benchmark internal performance and drive process improvement across multiple sites and complex organizational systems. For further information on IRBNet, please visit https://www.irbnet.org.

IRBNet and National Research Network are marks of Research Dataware, LLC. All rights are reserved and no use of the marks are permitted without the express written consent of Research Dataware, LLC.

About WIRB-Copernicus Group The nation's leading independent institutional review boards (IRB's) are united to provide a comprehensive ethical review solution to sponsors, CROs and institutions. Guided by a team of ethical and regulatory experts, WIRB-Copernicus Group deploys decades of experience and best-practices in protocol compliance, operational excellence, financial performance and overall efficiency. With more than 60 years of combined experience reviewing research protocols and study-related information, it is the mission of WIRB-Copernicus Group to meet the highest standards of ethics and science, and to ensure the safety and welfare of subjects worldwide. For more information, visit www.wcgirb.com.

CONTACT: press@irbnet.org

SOURCE IRBNet

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs